Zepbound approved for weight management, carrying a suicidal ideation warning

Eli Lilly's tirzepatide reached the US market a second time on Nov. 8, 2023, this time as Zepbound for chronic weight management. The same molecule already sold as Mounjaro for type 2 diabetes, tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist ^[1]. Zepbound was approved under its own application, NDA 217806 ^[2].

The notable difference between the two products was not the drug but the label. Zepbound launched with a Warnings and Precautions section on Suicidal Behavior and Ideation, a class-style caution that already appeared on other weight-management drugs including liraglutide (Saxenda) and semaglutide (Wegovy). Mounjaro, approved in 2022 for diabetes, did not carry that warning. The warning stayed on Zepbound's label for just over two years before being removed.

What the public record shows

FDA's Drug Safety-related Labeling Changes database tracks every safety revision to Zepbound's prescribing information by supplement number ^[2]. The excerpts available for this report begin with a Sept. 25, 2025 change (SUPPL-31) and continue through Feb. 25, 2026 (SUPPL-42); they do not include the original 2023 label text or the entry documenting the suicidal ideation warning's removal, so the exact wording and the exact removal date are not confirmed by the sources reviewed here ^[2].

What those later entries do show is how much the label has changed since launch. A February 2026 revision quantified severe gastrointestinal reactions in two Zepbound weight-reduction trials: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, versus 1% on placebo, and added that Zepbound is not recommended in patients with severe gastroparesis ^[2]. The same update expanded the postmarketing list to include acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, ileus, intestinal obstruction, and severe constipation including fecal impaction ^[2].

A September 2025 revision added trial numbers for pancreatitis: 0.2% of Zepbound-treated patients had adjudication-confirmed acute pancreatitis (0.14 patients per 100 years of exposure) versus 0.2% on placebo (0.15 per 100 years), while in the pooled obstructive sleep apnea studies the rate was 0.84 per 100 years for Zepbound and 0 for placebo ^[2]. That update also added acute renal failure or worsening chronic renal failure, sometimes requiring hemodialysis, to postmarketing experience ^[2]. A January 2026 change added a warning never to share a Zepbound KwikPen between patients, even with a new needle, because of blood-borne pathogen risk ^[2].

Why it matters for patients

The 2023 warning meant that anyone starting Zepbound received a Medication Guide telling them about possible suicidal thoughts or behavior, and prescribers were pointed toward monitoring for new or worsening depression and mood changes. Patients who began the drug in that window may remember that language; those starting later may see a different label. Labels are living documents, and the version handed out at a pharmacy reflects the most recent FDA-approved revision, not the one from launch.

It also shows that a warning appearing on one product and not another does not always mean the drugs differ. Mounjaro and Zepbound contain the same active ingredient at the same doses; the split came from how weight-management drugs had historically been labeled. What the provided sources do not establish is what evidence FDA weighed in adding the warning in 2023 or in removing it later.

What happens next

Tirzepatide's labels continue to move. FDA completed review of a Mounjaro supplement for pediatric type 2 diabetes on Nov. 26, 2025, ahead of a Dec. 19, 2025 goal date, with reviewers recommending approval for patients 10 years and older ^[1]. Zepbound's most recent safety labeling change in the record reviewed here is dated Feb. 25, 2026 ^[2].